Yadea Showcases Advanced Electric Two-Wheelers at IFA Berlin 2024, Leading the Way in Sustainable Mobility

BERLIN, Sept. 9, 2024 /PRNewswire/ -- The Internationale Funkausstellung Berlin (IFA), the top-tier international tech fair, opened in Berlin, Germany from September 6th to 10th. Coinciding with the 100th anniversary of IFA, Yadea, the world's largest electric two-wheeler brand, makes another appearance with its flagship electric bikes, electric scooters, and cutting-edge green riding technology, impressing the visitors and industry with its strong brand presence and product innovation.

At the show, Yadea delivered its high-quality kick scooters in Booth 2.2-310, including the ElitePrime, EliteMax, Artist, and KS6 Pro models, all ideal for city commuting and embodying a sustainable, eco-friendly lifestyle. It's worth mentioning that ElitePrime is equipped with advanced shock absorption and a maximum power output of 1500W, which can deliver a swift and smooth ride. Besides, its self-healing tubeless tires can be quickly filled with self-healing technology for seamless repairs when it comes to nail damage.

Another standout electric bike model, the Trooper01, is equally impressive. Equipped with a 250W motor, the Trooper01 features dual suspension and wide tires for enhanced road handling, and its retro motorcycle design has gained significant popularity among young international users. And it has been tested and certified by the esteemed TUV SUD laboratory, meeting the EN15194 safety standard, which makes it a highly reliable electric bike for the European market.

This year, Yadea's participation at IFA goes beyond just showcasing its latest products. The brand is leveraging the event as a strategic platform to explore new opportunities for business collaboration. By fostering relationships with international distributors and retailers, Yadea aims to  further establish itself as a leading player in the sustainable mobility sector.

Yadea continues to lead the electric two-wheeler market, maintaining the top sales spot for seven consecutive years. All products on display meet strict European certification standards, and the company has earned recognition for its innovation in green mobility, holding over 1,900 patents, two national CNAS laboratories, and six R&D centers. Yadea's strategic global expansion is further supported by its eight production bases, including key facilities in Indonesia and Vietnam, catering to its growing international footprint.

As the global demand for sustainable transportation grows, Yadea's commitment to green mobility remains at the forefront of its mission. With its pioneering technology and dedication to reducing carbon emissions, the company continues to make significant strides toward a cleaner, more environmentally friendly future.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Yadea Showcases Advanced Electric Two-Wheelers at IFA Berlin 2024, Leading the Way in Sustainable Mobility

BARCELONA, Spain, Sept. 17, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour mRNA vaccine, WGc-043, during a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024.

Pioneering Advances in mRNA Therapeutics

WGc-043, the world's first mRNA therapeutic vaccine targeting EBV-positive tumors to achieve IND approval in both China and the US, demonstrated exceptional safety, immunogenicity, and anti-tumor activity in the latest clinical trials. The vaccine is being developed specifically for adult patients with advanced EBV-positive solid tumours and refractory or relapsed EBV-positive lymphomas, diseases for which there are currently no effective, low-toxicity treatment options.

Impressive Clinical Performance Recognized by ESMO

Interim clinical data presented at ESMO 2024 highlighted the vaccine's ability to activate the patient's immune system, leading to the production of cytotoxic T cells, antigen-specific antibodies and memory T cells that target and destroy cancer cells. This novel mechanism offers a promising alternative to conventional CAR-T and monoclonal antibody therapies and also aims to prevent tumor recurrence, providing a triple benefit, particularly for patients with late-stage nasopharyngeal carcinoma and NK/T cell lymphoma.

Innovative Technology and Global Impact

WGc-043 is a testament to WestGene's proprietary mRNA platform, which includes cutting-edge innovations in mRNA sequence design, novel lipid nanoparticle (LNP) delivery systems, and scalable manufacturing processes. The vaccine was developed using WestGene's patented LNP technology, which is recognized for its superior efficacy and safety. This technology has been instrumental in overcoming the challenges associated with mRNA vaccine delivery and has positioned WestGene as a leader in the global mRNA therapeutic

Expanding Horizons in Cancer Treatment

The global market for mRNA cancer vaccines is expected to grow significantly, with estimates ranging from $230 billion to $300 billion by 2035. The success of WGc-043 at ESMO underscores the potential of mRNA technology not only to lead the field, but also to accelerate clinical development and provide safe, effective treatments for late-stage cancer patients.

Looking Ahead

WestGene Biopharma (www.westgenepharma.com) remains committed to advancing its mRNA platform and expanding its pipeline to address unmet medical needs across a range of indications. The company's innovative approach and commitment to collaboration will continue to drive progress in the field of mRNA therapeutics and bring hope to patients worldwide.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024